|
|
| | Thalidomide-O-amide-C5-NH2 TFA Basic information |
| Product Name: | Thalidomide-O-amide-C5-NH2 TFA | | Synonyms: | Thalidomide-O-amide-C5-NH2 TFA;N-(5-Aminopentyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide 2,2,2-trifluoroacetate;Acetamide, N-(5-aminopentyl)-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]-, 2,2,2-trifluoroacetate (1:1) | | CAS: | 2748161-83-1 | | MF: | C20H24N4O6.C2HF3O2 | | MW: | 530.45 | | EINECS: | | | Product Categories: | | | Mol File: | 2748161-83-1.mol |  |
| | Thalidomide-O-amide-C5-NH2 TFA Chemical Properties |
| | Thalidomide-O-amide-C5-NH2 TFA Usage And Synthesis |
| Uses | Thalidomide-O-amide-C5-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. | | IC 50 | Cereblon | | References | [1] Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. DOI:10.3389/fcell.2021.629326
[2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. DOI:10.7554/eLife.57277 |
| | Thalidomide-O-amide-C5-NH2 TFA Preparation Products And Raw materials |
|